Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?

Abstract

A B S T R A C T PurposeTo determine if older patients with breast cancer have cognitive impairment before systemic therapy. Patients and MethodsParticipants were patients with newly diagnosed nonmetastatic breast cancer and matched friend or community controls age Ͼ 60 years without prior systemic treatment, dementia, or neurologic disease. Participants completed surveys and a 55-minute battery of 17 neuropsychological tests. Biospecimens were obtained for APOE genotyping, and clinical data were abstracted. Neuropsychological test scores were standardized using control means and standard deviations (SDs) and grouped into five domain z scores. Cognitive impairment was defined as any domain z score two SDs below or Ն two z scores 1.5 SDs below the control mean. Multivariable analyses evaluated pretreatment differences considering age, race, education, and site; comparisons between patient cases also controlled for surgery. ResultsThe 164 patient cases and 182 controls had similar neuropsychological domain scores. However, among patient cases, those with stage II to III cancers had lower executive function compared with those with stage 0 to I disease, after adjustment (P ϭ .05). The odds of impairment were significantly higher among older, nonwhite, less educated women and those with greater comorbidity, after adjustment. Patient case or control status, anxiety, depression, fatigue, and surgery were not associated with impairment. However, there was an interaction between comorbidity and patient case or control status; comorbidity was strongly associated with impairment among patient cases (adjusted odds ratio, 8.77; 95% CI, 2.06 to 37.4; P ϭ .003) but not among controls (P ϭ .97). Only diabetes and cardiovascular disease were associated with impairment among patient cases. ConclusionThere were no overall differences between patients with breast cancer and controls before systemic treatment, but there may be pretreatment cognitive impairment within subgroups of patient cases with greater tumor or comorbidity burden.

Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study

“…Cognitive decline over time raises the question of whether patients with cancer, particularly those who receive chemotherapy, may be at risk for accelerated cognitive aging. 18,19 Those with lower preexisting cognitive reserve are expected to be at greater risk 20,21 ; although our study did not show such an effect, it is confounded because those with less cognitive reserve were more likely to drop out. Longer follow-up is required to address this issue.…”

Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: Major impact of cognition

“…Third, older people with cognitive impairment are more frequently isolated (34), and turn away persons who want to help, to avoid facing their difficulties (35). Finally, it is increasingly reported that chemotherapeutic agents can worsen the patient's cognitive status (36)(37)(38). Thus, it is obvious those patients with cognitive impairment at the start of chemotherapy are more vulnerable, and that their vulnerability can be worsened by chemotherapeutic agents (39,40).…”

“…Patients with cognitive impairment should definitely be identified and steered towards rehabilitation and adapted care (38), including psychological support (35). More generally, health services should be adapted to the needs of this vulnerable population (need for services to be organized at the bedside and flexibility in scheduling appointments).…”

Toward a National Initiative in Cancer Rehabilitation: Recommendations From a Subject Matter Expert Group

“…101 Evidence suggests that preexisting cognitive impairment, in many instances mild or subclinical, may be exacerbated during cancer treatment. 102 Therefore, a comprehensive cancer rehabilitation model that includes prehabilitation or pretreatment assessment should seek to establish a cognitive baseline to optimize proactive screening. 103 …”